Implantica AG Expands RefluxStop™ Center of Excellence in Spain.

Implantica AG, a medtech company, has announced a new Center of Excellence in Spain for its RefluxStop™ device, which treats acid reflux affecting 1 billion people. The first procedures were performed by leading surgeon Dra. Sonia Castanedo at H. Univ. Marqués de Valdecilla in Cantabria, Spain. The hospital is a flagship research center focused on innovative therapies like RefluxStop™.

Implantica AG, a leading medtech company, has announced the establishment of a new Center of Excellence in Spain for its innovative RefluxStop™ device. The center, located at H. Univ. Marqués de Valdecilla in Cantabria, is the latest addition to the company's global network of centers dedicated to advanced anti-reflux treatment.

The first procedures using RefluxStop™ were performed by Dr. Sonia Castanedo, a leading surgeon at H. Univ. Marqués de Valdecilla. The hospital, renowned for its research in innovative therapies, is the flagship center for Cantabria, situated in northern Spain. The RefluxStop™ device offers a durable surgical solution for GERD (Gastroesophageal Reflux Disease), addressing the significant demand for effective treatment options in the region.

The RefluxStop™ device is designed to treat the root cause of acid reflux without encircling and putting pressure on the food passageway, unlike traditional surgical options. This unique mechanism allows it to be available to a broader range of GERD patients who may not have been suitable candidates for conventional anti-reflux surgery. The device restores and maintains the lower oesophageal sphincter in its natural position, offering a paradigm shift in anti-reflux treatment.

The demand for RefluxStop™ is growing rapidly, as indicated by the increasing prevalence of GERD in Spain. According to a study by the Iberge Study Group, approximately 15% of the adult population in Spain suffers from GERD [1]. For about 40% of these patients, medication alone is insufficient to manage the symptoms [2]. This leaves a substantial need for a well-functioning surgical treatment, which RefluxStop™ aims to address.

Implantica AG, listed on Nasdaq First North Premier Growth Market, is committed to bringing advanced technology into the body. The company's focus on eHealth and wireless energizing platforms underscores its dedication to innovation and patient care. The establishment of the new center in Cantabria is a significant step in expanding the company's reach and providing more patients with access to effective treatment options.

References:
[1] Ponce J, Vegazo O, Beltrán B, Jiménez J, Zapardiel J, Calle D, Piqué JM; Iberge Study Group. Prevalence of gastro-oesophageal reflux disease in Spain and associated factors. Aliment Pharmacol Ther. 2006 Jan 1;23(1):175-84. doi: 10.1111/j.1365-2036.2006.02733.x. PMID: 16393295.
[2] Kahrilas PJ, Boeckxstaens G, Smout AJ. Management of the patient with incomplete response to PPI therapy. Best Pract Res Clin Gastroenterol. 2013 Jun;27(3):401-14. doi: 10.1016/j.bpg.2013.06.005. PMID: 23998978; PMCID: PMC3761380.